Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 02 Apr 2025 According to a Mesoblast media release, the company provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval pathway for Revascor(rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation.
- 26 Mar 2019 Status changed from active, no longer recruiting to completed, according to a Mesoblast media release.
- 28 Dec 2018 According to a Mesoblast media release, based on the outcomes of this study, the company plans to meet with the FDA In the first half of 2019 to discuss a potential approval pathway for MPC-150-IM.